Telangiectasis
MONDO:0001576Local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.
Also known as: telangiectasia
44 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a cancer drug spray stop debilitating nosebleeds?
Disease control CompletedThis trial tests whether a nasal spray containing bevacizumab, a drug typically used for cancer, can reduce frequent nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). The study enrolls 20 adults who have at least 10 nosebleeds per month. The goal is to see if…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
HHT nosebleed drug shows promise in long-term follow-up study
Disease control CompletedThis study follows 62 adults with hereditary hemorrhagic telangiectasia (HHT) who previously took pomalidomide in a clinical trial. Researchers want to see if the drug safely reduces nosebleed severity and the need for iron or blood transfusions over time. Participants take pomal…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a transplant drug stop HHT nosebleeds? small study tests sirolimus
Disease control CompletedThis small pilot study tested the safety and effectiveness of the oral drug sirolimus for reducing nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). Ten adults with moderate to severe nosebleeds took 2 mg of sirolimus daily for 3 months. Researchers tracked b…
Phase: PHASE2 • Sponsor: Unity Health Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Drug could offer alternative to liver transplant for rare bleeding disorder
Disease control CompletedThis study tested a drug called bevacizumab in 25 adults with hereditary hemorrhagic telangiectasia (HHT) who had severe liver issues and high heart output. The goal was to see if the drug could improve heart function and reduce the need for a liver transplant, which requires lif…
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New ultra-low-dose CT scan aims to protect kids with rare blood vessel disorder
Diagnosis CompletedThis study tested a new ultra-low-dose chest CT technique in 3 children (ages 1-17) with hereditary hemorrhagic telangiectasia (HHT) to see if it could detect abnormal blood vessels in the lungs (PAVMs) using much less radiation than standard CT. The goal was to find the lowest p…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
AI matches doctors in spotting early vein disease
Diagnosis CompletedThis study tested whether an AI app (IVENUS) could correctly classify the severity of chronic vein disease from leg photos. Over 1,600 patients had their legs photographed, and the app's diagnosis was compared to that of experienced doctors. The goal was to see if the app could r…
Phase: NA • Sponsor: Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
New ultra-low dose CT could slash radiation for HHT lung checks
Diagnosis CompletedThis study tested whether an ultra-low dose chest CT scan can find lung blood vessel malformations in people with hereditary hemorrhagic telangiectasia (HHT) as well as the standard low-dose CT scan, but with much less radiation. 45 HHT patients received both scans, and radiologi…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 26, 2026 15:38 UTC
-
Laser zaps face veins in scleroderma patients – 21 test it out
Symptom relief CompletedThis study tested a pulsed dye laser to reduce red veins (telangiectasias) on the face and neck in 21 people with scleroderma. Participants received four laser sessions, and the researchers checked how many veins disappeared, how patients felt about the results, and any side effe…
Phase: NA • Sponsor: University Hospital, Caen • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New gel shows promise for rosacea redness in small study
Symptom relief CompletedThis study tested a gel containing brimonidine to see if it can reduce persistent facial redness in people with rosacea. In the first part, 45 adults applied the gel to one side of their face and a placebo to the other, measuring redness after a few hours. In the second part, the…
Phase: PHASE4 • Sponsor: Istanbul Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New laser zaps dry eye by targeting blood vessels on eyelids
Symptom relief CompletedThis study tested a gentle laser (micropulse) on 30 people with dry eye from meibomian gland dysfunction. The laser targets tiny blood vessels on the eyelid edge to reduce inflammation and improve tear quality. Researchers measured tear stability and symptom scores to see if the …
Phase: NA • Sponsor: Naval Hospital, Athens • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Large study aims to predict brain bleeds in rare HHT disorder
Knowledge-focused CompletedThis study looked at over 2,200 people with hereditary hemorrhagic telangiectasia (HHT), a rare condition that causes abnormal blood vessels. The goal was to find out what makes some people with HHT more likely to have a brain bleed. Researchers collected health information, bloo…
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Exercise echo may catch silent heart failure in rare HHT liver disease
Knowledge-focused CompletedThis completed pilot study looked at 47 adults with hereditary hemorrhagic telangiectasia (HHT) who also have liver involvement. Researchers used exercise echocardiography (heart ultrasound while pedaling) to measure lung artery pressure during exercise. The goal was to see if th…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New study reveals how HHT symptoms impact daily life
Knowledge-focused CompletedThis study looked at how symptoms of hereditary hemorrhagic telangiectasia (HHT) affect patients' quality of life. Researchers used a special questionnaire developed with patient input to measure different aspects like physical limits, worry about bleeding, and social relationshi…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Cord blood study could unlock new HHT treatments
Knowledge-focused CompletedThis study collected umbilical cord blood and tissue from 16 newborns who have a parent with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder causing abnormal blood vessels. Researchers aim to grow and compare endothelial cells from these babies with cells from hea…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:00 UTC